What question did this study set out to answer?

To evaluate the therapeutic impact of reslizumab on symptom severity, clinical characteristics, and eosinophilic markers in patients suffering from severe eosinophilic asthma and comorbid chronic rhinosinusitis.

June 20, 2023South East European Journal of ImmunologyOpen Access

Chronic Rhinosinusitis with Polyps and Comorbid Asthma: Results of Reslizumab Treatment

View Full Paper

Ask AI

Bookmark

Authors

НБН. В. БойкоRostov State Medical University ISI.V. StagnievaRostov State Medical University ОЛО.Е. ЛодочкинаRostov State Medical University

Discussion

Member takes

Implication

Prospective interventional study demonstrates improved nasal and asthma symptoms in comorbid patients treated with reslizumab, suggesting shared eosinophilic pathway targeting.

Key Points

To evaluate the therapeutic impact of reslizumab on symptom severity, clinical characteristics, and eosinophilic markers in patients suffering from severe eosinophilic asthma and comorbid chronic rhinosinusitis.
Interventional study of 18 patients with severe eosinophilic asthma treated with intravenous reslizumab at 3 mg/kg every 4 weeks for 6 doses.
Outcomes were evaluated at baseline and after 6 injections using SNOT-22, Asthma Control Test (ACT), nasal endoscopy, sinus CT, rhinocytogram, blood eosinophil count, eosinophil cationic protein, and spirometry.
Administration of 6 reslizumab doses resulted in significant improvements in asthma control and reductions in chronic rhinosinusitis symptom severity (p < 0.05).
Reductions in asthma symptoms were more pronounced in patients with severe eosinophilic asthma who had comorbid chronic rhinosinusitis with nasal polyps compared to those without polyps.

Cite This Study

Бойко et al. (2023) studied this question.

synapsesocial.com/papers/6a7f72f657c5f8e54d65728f https://doi.org/10.3889/seejim.2023.6039

View Full Paper

Ask AI

Bookmark

Implication

Prospective interventional study demonstrates improved nasal and asthma symptoms in comorbid patients treated with reslizumab, suggesting shared eosinophilic pathway targeting.

Chronic Rhinosinusitis with Polyps and Comorbid Asthma: Results of Reslizumab Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Chronic Rhinosinusitis with Polyps and Comorbid Asthma: Results of Reslizumab Treatment

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider